Roles of Ambient Temperature and PM2.5 on Childhood Acute Bronchitis and Bronchiolitis from Viral Infection

Viruses. 2022 Aug 30;14(9):1932. doi: 10.3390/v14091932.

Abstract

Studies have associated the human respiratory syncytial virus which causes seasonal childhood acute bronchitis and bronchiolitis (CABs) with climate change and air pollution. We investigated this association using the insurance claims data of 3,965,560 children aged ≤ 12 years from Taiwan from 2006−2016. The monthly average incident CABs increased with increasing PM2.5 levels and exhibited an inverse association with temperature. The incidence was 1.6-fold greater in January than in July (13.7/100 versus 8.81/100), declined during winter breaks (February) and summer breaks (June−August). The highest incidence was 698 cases/day at <20 °C with PM2.5 > 37.0 μg/m3, with an adjusted relative risk (aRR) of 1.01 (95% confidence interval [CI] = 0.97−1.04) compared to 568 cases/day at <20 °C with PM2.5 < 15.0 μg/m3 (reference). The incidence at ≥30 °C decreased to 536 cases/day (aRR = 0.95, 95% CI = 0.85−1.06) with PM2.5 > 37.0 μg/m3 and decreased further to 392 cases/day (aRR = 0.61, 95% CI = 0.58−0.65) when PM2.5 was <15.0 μg/m3. In conclusion, CABs infections in children were associated with lowered ambient temperatures and elevated PM2.5 concentrations, and the high PM2.5 levels coincided with low temperature levels. The role of temperature should be considered in the studies of association between PM2.5 and CABs.

Keywords: acute bronchitis and bronchiolitis; ambient temperature; fine particulate matter; human respiratory syncytial virus; temperature inversion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Bronchiolitis* / epidemiology
  • Bronchiolitis* / etiology
  • Bronchitis* / epidemiology
  • Bronchitis* / etiology
  • Child
  • Environmental Exposure / adverse effects
  • Humans
  • Particulate Matter / adverse effects
  • Particulate Matter / analysis
  • Temperature
  • Virus Diseases*

Substances

  • Particulate Matter

Grants and funding

This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW110-TDU-B-212-124004), Ministry of Science and Technology (MOST 110-2321-B-039-003), and China Medical University Hospital (DMR-111-228). The funders have no role in the study design, data collection and analysis, the decision to publish, or preparation of the manuscript.